CHIRON ACQUIRES SHARE IN VIAGENE

6 December 1993

US biotechnology company Chiron, which is collaborating with Viagene of San Diego, California, in the development of anticancer and treatments for other diseases using genetic technology, has acquired a 19.4% holding in Viagene, by investing $32 million in equity and initial research funding.

Under the terms of the agreement, R&D costs will be divided equally between the two companies but with Viagene footing the bill for the first $12 million. Viagene will also be responsible for preclinical research, while Chiron will undertake clinical trials and registration. After the first $24 million the two companies will split the cost of R&D.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight